Total and Acylated Ghrelin Levels in Type 2 Diabetic Patients: Similar Levels Observed after Treatment with Metformin, Pioglitazone or Diet Therapy

Abstract

Ghrelin, a potent gut-brain orexigenic peptide, has a role in stimulation of food intake and long-term regulation of body weight. Metformin and pioglitazone treatment have different effects on body weight. This discrepancy might be related with the effect of these two drugs on plasma ghrelin levels. We investigated the effect of these two drugs on post-prandial acylated and total ghrelin levels in patients with type 2 diabetes. Eleven patients treated with diet, 12 patients treated with 850 mg/day metformin monotherapy and 12 patients treated with 30 mg/day pioglitazone monotherapy for at least 6 months were enrolled in the study. Plasma acylated and total ghrelin levels were investigated at baseline and at the 60^th, 120^th, 180^th, 240^th minutes after a mixed meal test. There were no differences between groups in any of baseline metabolic and anthropometric parameters, including acylated and total ghrelin levels. Acylated and total ghrelin concentrations were suppressed similarly after food consumption, and we could not determine any significant difference between the groups at any time interval. A prolonged postprandial suppression of acylated ghrelin concentrations was observed in the pioglitazone treatment group compared with baseline values. In conclusion, total and acylated ghrelin levels after a mixed meal test were similar in type 2 diabetic patients treated with metformin, pioglitazone or diet therapy alone. These results suggest that changes in body weight during metformin and pioglitazone treatment are not associated with plasma ghrelin levels.

Key words

ghrelin - type 2 diabetes - metformin - pioglitazone

References

• 1 Al Awar R, Obeid O, Hwalla N. et al . Postprandial acylated ghrelin status following fat and protein manipulation of meals in healthy young women.  Clin Sci (Lond). 2005;  109 ((4)) 405-411
• 2 Ariyasu H, Takaya K, Tagami T. et al . Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans.  J Clin Endocrinol Metab. 2001;  86 ((10)) 4753-4758
• 3 Asakawa A, Inui A, Fujimiya M. et al . Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin.  Gut. 2005;  54 ((1)) 18-24
• 4 Cummings DE, Purnell JQ, Frayo RS. et al . A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans.  Diabetes. 2001;  50 ((8)) 1714-1719
• 5 Date Y, Kojima M, Hosoda H. et al . Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans.  Endocrinology. 2000;  141 ((11)) 4255-4261
• 6 English PJ, Ashcroft A, Patterson M. et al . Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetes.  Diabetes Metab Res Rev. 2007;  23 ((4)) 299-303
• 7 Fricke O, Lehmkuhl G, Schoenau E. The principle of regulation in biology – from bone to eating behavior.  Exp Clin Endocrinol Diabetes. 2006;  114 ((4)) 197-203
• 8 Golay A. Metformin and body weight.  Int J Obes (Lond). 2008;  32 ((1)) 61-72
• 9 Hosoda H, Kojima M, Matsuo H. et al . Purification and characterization of rat des-Gln14-Ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor.  J Biol Chem. 2000;  275 ((29)) 21995-22000
• 10 Kempa A, Krzyzanowska-Swiniarska B, Miazgowski T. et al . Not insulin but insulin sensitivity, leptin, and cortisol are major factors regulating serum acylated ghrelin level in healthy women.  J Endocrinol Invest. 2007;  30 ((8)) 659-665
• 11 Kojima M, Hosoda H, Date Y. et al . Ghrelin is a growth-hormone-releasing acylated peptide from stomach.  Nature. 1999;  402 ((6762)) 656-660
• 12 Kusaka I, Nagasaka S, Horie H. et al . Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability?.  Diabetes Obes Metab. 2008;  10 ((11)) 1039-1046
• 13 Lindberg M, Astrup A. The role of glitazones in management of type 2 diabetes. A dream or a nightmare?.  Obes Rev. 2007;  8 ((5)) 381-384
• 14 Lucidi P, Murdolo G, Di Loreto C. et al . Meal intake similarly reduces circulating concentrations of octanoyl and total ghrelin in humans.  J Endocrinol Invest. 2004;  27 ((5)) 12-15
• 15 Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus.  Diabetologia. 1999;  42 ((4)) 406-412
• 16 McLaughlin T, Abbasi F, Lamendola C. et al . Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls.  J Clin Endocrinol Metab. 2004;  89 ((4)) 1630-1635
• 17 Monteleone P, Bencivenga R, Longobardi N. et al . Differential responses of circulating ghrelin to high-fat or high-carbohydrate meal in healthy women.  Clin Endocrinol Metab. 2003;  88 ((11)) 5510-5514
• 18 Nakagawa E, Nagaya N, Okumura H. et al . Hyperglycaemia suppresses the secretion of ghrelin, a novel growth-hormone-releasing peptide: responses to the intravenous and oral administration of glucose.  Clin Sci (Lond). 2002;  103 ((3)) 325-328
• 19 Nakazato M, Murakami N, Date Y. et al . A role for ghrelin in the central regulation of feeding.  Nature. 2001;  409 ((6817)) 194-198
• 20 Otto C, Otto B, Göke B. et al . Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels.  J Endocrinol Invest. 2006;  29 ((3)) 231-236
• 21 Saad MF, Bernaba B, Hwu CM. et al . Insulin regulates plasma ghrelin concentration.  J Clin Endocrinol Metab. 2002;  87 ((8)) 3997-4000
• 22 Saitoh Y, Liu R, Ueno H. et al . Oral pioglitazone administration increases food intake through ghrelin-independent pathway in Zucker fatty rat.  Diabetes Res Clin Pract. 2007;  77 ((3)) 351-356
• 23 Seufert J, Lübben G, Dietrich K. et al . A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.  Clin Ther. 2004;  26 ((6)) 805-818
• 24 Smith SR, De Jonge L, Volaufova J. et al . Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.  Metabolism. 2005;  54 ((1)) 24-32
• 25 Tannous dit El Khoury D, Obeid O, Azar ST. et al . Variations in postprandial ghrelin status following ingestion of high-carbohydrate, high-fat, and high-protein meals in males.  Ann Nutr Metab. 2006;  50 ((3)) 260-269
• 26 Toshinai K, Yamaguchi H, Sun Y. et al . Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor.  Endocrinology. 2006;  147 ((5)) 2306-2314
• 27 Tschöp M, Weyer C, Tataranni PA. et al . Circulating ghrelin levels are decreased in human obesity.  Diabetes. 2001;  50 ((4)) 707-709
• 28 UK prospective diabetes study 16 . Overview of 6 years’ therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group.  Diabetes. 1995;  44 1249-1258
• 29 Wang J, Ling S, Usami T. et al . Effects of ghrelin, corticotrophin-releasing hormone, and melanotan-II on food intake in rats with paraventricular nucleus lesions.  Exp Clin Endocrinol Diabetes. 2007;  115 ((10)) 669-673
• 30 Woelfle JF, Harz K, Roth C. Modulation of circulating IGF-I and IGFBP-3 levels by hormonal regulators of energy homeostasis in obese children.  Exp Clin Endocrinol Diabetes. 2007;  115 ((1)) 17-23
• 31 Vestergaard ET, Djurhuus CB, Gjedsted J. et al . Acute effects of ghrelin administration on glucose and lipid metabolism.  J Clin Endocrinol Metab. 2008;  93 ((2)) 438-444
• 32 Yki-Järvinen H, Nikkilä K, Mäkimattila S. Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus.  Drugs. 1999;  58 ((Suppl 1)) 53-54 , ; discussion 75–82.

Correspondence